Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 14/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13915990 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL4031493 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL20250240 | 0.86 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL3745740 | 0.84 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL13835677 | 0.84 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL6023093 | 0.84 | SLC6A2 (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL12694069 | 0.82 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL15433976 | 0.82 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL27946788 | 0.82 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL14143440 | 0.82 | SLC6A2 (0.68) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569579-B2 | for inhibition of HIV replication and treatment of acquired immune deficiency syndrome | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1569934-B1 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20060052408-A1 | Cyclopropyl compounds as ccr5 antagonists | SMITHKLINE BEECHAM CORPORATION | 2006-03-09 | — | — | US | disclosed |
| EP-1569934-A2 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004055010-A2 | CYCLOPROPYL COMPOUNDS AS CCR5 ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052408-A1 | Cyclopropyl compounds as ccr5 antagonists | CCR5, CCR1, CCL5 | SLC6A2 1961/4885SLC6A4 1697/4885SLC6A3 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.